[go: up one dir, main page]

PT3658147T - Combinação compreendendo palbociclib e 6-(2,4- diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidina-3- il]oxifenil]-8,9-diidro-7h-benzo[7] ácido anuleno-2- carboxílico e seu uso para o tratamento do cancro - Google Patents

Combinação compreendendo palbociclib e 6-(2,4- diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidina-3- il]oxifenil]-8,9-diidro-7h-benzo[7] ácido anuleno-2- carboxílico e seu uso para o tratamento do cancro

Info

Publication number
PT3658147T
PT3658147T PT187406152T PT18740615T PT3658147T PT 3658147 T PT3658147 T PT 3658147T PT 187406152 T PT187406152 T PT 187406152T PT 18740615 T PT18740615 T PT 18740615T PT 3658147 T PT3658147 T PT 3658147T
Authority
PT
Portugal
Prior art keywords
annulene
palbociclib
oxyphenyl
fluoropropyl
pyrrolidin
Prior art date
Application number
PT187406152T
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT3658147T publication Critical patent/PT3658147T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187406152T 2017-07-25 2018-07-23 Combinação compreendendo palbociclib e 6-(2,4- diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidina-3- il]oxifenil]-8,9-diidro-7h-benzo[7] ácido anuleno-2- carboxílico e seu uso para o tratamento do cancro PT3658147T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305998.1A EP3434272A1 (en) 2017-07-25 2017-07-25 Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Publications (1)

Publication Number Publication Date
PT3658147T true PT3658147T (pt) 2022-02-02

Family

ID=59569252

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187406152T PT3658147T (pt) 2017-07-25 2018-07-23 Combinação compreendendo palbociclib e 6-(2,4- diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidina-3- il]oxifenil]-8,9-diidro-7h-benzo[7] ácido anuleno-2- carboxílico e seu uso para o tratamento do cancro

Country Status (30)

Country Link
US (2) US11260057B2 (pt)
EP (2) EP3434272A1 (pt)
JP (1) JP6741897B1 (pt)
KR (1) KR20200031622A (pt)
CN (1) CN111107851B (pt)
AR (1) AR112284A1 (pt)
AU (1) AU2018308871A1 (pt)
BR (1) BR112020001398A2 (pt)
CA (1) CA3070754A1 (pt)
CO (1) CO2020000240A2 (pt)
DK (1) DK3658147T3 (pt)
ES (1) ES2906279T3 (pt)
HR (1) HRP20212030T1 (pt)
HU (1) HUE057271T2 (pt)
IL (1) IL272166B2 (pt)
LT (1) LT3658147T (pt)
MA (1) MA49673B1 (pt)
MX (1) MX393852B (pt)
MY (1) MY195271A (pt)
PH (1) PH12020500091A1 (pt)
PL (1) PL3658147T3 (pt)
PT (1) PT3658147T (pt)
RS (1) RS62837B1 (pt)
RU (1) RU2764116C2 (pt)
SG (1) SG11202000367RA (pt)
SI (1) SI3658147T1 (pt)
TW (1) TWI768087B (pt)
UY (1) UY37818A (pt)
WO (1) WO2019020559A1 (pt)
ZA (1) ZA202000145B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112638869B (zh) 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
KR20220006553A (ko) * 2019-05-09 2022-01-17 사노피 전이성 또는 진행성 유방암 환자에서 사용하기 위한 6-(2,4-디클로로페닐)-5-[4-[(3s)-1-(3-플루오로프로필)피롤리딘-3-일]옥시페닐]-8,9-디하이드로-7h-벤조[7]아눌렌-2-카르복실산
JP2023504912A (ja) * 2019-12-09 2023-02-07 サノフイ ７ｈ－ベンゾ［７］アヌレン－２－カルボン酸誘導体の結晶形態
TW202146007A (zh) * 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN116782895A (zh) * 2020-11-23 2023-09-19 赛诺菲 包含阿贝西利和6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸的组合
TW202302084A (zh) * 2021-03-02 2023-01-16 法商賽諾菲公司 以安森司坦和帕博西尼治療乳癌
TW202304425A (zh) * 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
KR102815360B1 (ko) 2022-03-03 2025-06-02 인하대학교 산학협력단 암의 예방 또는 치료용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE60108354T2 (de) 2001-01-24 2006-01-05 Chiesi Farmaceutici S.P.A. 2H-1-Benzopyranderivate, Verfahren zu ihrer Herstellung und deren pharmazeutische Zusammensetzungen
WO2003016270A2 (en) 2001-08-11 2003-02-27 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
ES2350446T3 (es) 2002-04-24 2011-01-24 MERCK SHARP & DOHME CORP. Moduladores de los receptores de estrógenos.
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
MX2007000036A (es) 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
US7429681B2 (en) 2005-06-14 2008-09-30 Baylor University Combretastatin analogs with tubulin binding activity
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2655367B1 (en) 2010-12-24 2016-07-06 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2015504049A (ja) 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドＣｅｎｔａｕｒｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
KR20240160682A (ko) * 2013-08-14 2024-11-11 노파르티스 아게 암의 치료를 위한 조합 요법
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN107108611B (zh) 2014-12-18 2020-09-25 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
CN106924210A (zh) * 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
HRP20211043T1 (hr) 2016-02-15 2021-10-01 Sanofi Derivati 6,7-dihidro-5h-benzo[7]anulena kao modulatori estrogenskih receptora
EP3541809B1 (en) 2016-11-17 2025-06-25 Sanofi Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN112638869B (zh) 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
KR20210093946A (ko) * 2018-11-16 2021-07-28 아르퀼 인코포레이티드 암의 치료를 위한 제약 조합물

Also Published As

Publication number Publication date
AU2018308871A1 (en) 2020-02-06
ES2906279T3 (es) 2022-04-18
MY195271A (en) 2023-01-11
HUE057271T2 (hu) 2022-04-28
LT3658147T (lt) 2022-01-10
JP2020526572A (ja) 2020-08-31
BR112020001398A2 (pt) 2020-07-28
EP3658147B1 (en) 2021-11-10
IL272166B (en) 2022-12-01
TWI768087B (zh) 2022-06-21
EP3658147A1 (en) 2020-06-03
SG11202000367RA (en) 2020-02-27
AR112284A1 (es) 2019-10-09
RU2020107416A3 (pt) 2021-08-25
MX393852B (es) 2025-03-24
EP3434272A1 (en) 2019-01-30
DK3658147T3 (da) 2022-01-31
IL272166B2 (en) 2023-04-01
CN111107851A (zh) 2020-05-05
CA3070754A1 (en) 2019-01-31
MA49673A (fr) 2021-03-24
US11260057B2 (en) 2022-03-01
KR20200031622A (ko) 2020-03-24
JP6741897B1 (ja) 2020-08-19
TW201919612A (zh) 2019-06-01
WO2019020559A1 (en) 2019-01-31
RU2020107416A (ru) 2021-08-25
HRP20212030T1 (hr) 2022-04-01
PL3658147T3 (pl) 2022-03-07
RU2764116C2 (ru) 2022-01-13
US20200171033A1 (en) 2020-06-04
CN111107851B (zh) 2023-05-12
UY37818A (es) 2020-08-31
PH12020500091A1 (en) 2020-09-14
CO2020000240A2 (es) 2020-04-24
RS62837B1 (sr) 2022-02-28
MA49673B1 (fr) 2022-02-28
IL272166A (en) 2020-03-31
SI3658147T1 (sl) 2022-02-28
ZA202000145B (en) 2021-07-28
US20220362248A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
IL272166A (en) A combination containing palbociclib and 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo [7] Anolin-2 carboxylic acid and its use in cancer treatment
IL281191A (en) Salts of methyl 6-(4,2-dichlorophenyl)-5-[4-[(S3)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-9,8-dihydro-H7-benzo[7 ]anolene-2-carboxylate and processes for their preparation
EP4559481A3 (en) Methods of treatment of cholestatic diseases
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
MY191956A (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
GB2552063B (en) Medical scope accessory, medical scopes comprising the accessory, and use thereof
IL287805A (en) 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene -2-carboxylic for use in metastatic or advanced breast cancer patients
ZA202004548B (en) Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
SI3313818T1 (sl) Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
EP3246037A4 (en) Crosslinked chondroitin sulfate, composition containing same, and treatment agent for eye disease
SG11201809760TA (en) Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
LT3362094T (lt) Derinys, apimantis aminotiolesterio junginį arba farmaciniu požiūriu priimtiną jo druską ir junginį, galintį padidinti h2o2 lydį subjekto vėžinėse ląstelėse
SG11202100269VA (en) Compounds for use in the treatment of fascioliasis
HK40019959A (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
EP3646872A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
HK40063160A (en) 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients
IL266099B (en) N-((4r,3s)-1-(8-chloroquinoxaline-6-yl)carbonyl)-3-(4-fluorophenyl)-piperidine-4-yl)-1-methyl-5-(trifluoromethyl)-1h- Pyrazole-3-carboxamide and its medical use
HK40010513A (en) 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
HK1225024A1 (en) (r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders